Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuanbin Ru

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
The Lancet. Oncology|January 25, 2011
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessmentSteven Christopher Smith, Alexander Spyridon Baras, Garrett Dancik, et al.
Annals of Clinical and Translational Neurology|December 10, 2019
Neurofilament light is a treatment-responsive biomarker in CLN2 diseaseYuanbin Ru, Carley Corado, Russell K Soon, et al.
Military Medicine|November 1, 2017
Comparative Survival Analysis of Invasive Breast Cancer Patients Treated by a U.S. Military Medical Center and Matched Patients From the U.S. General PopulationYuanbin Ru, Jianfang Liu, J Leigh Fantacone-Campbell, et al.
Nature Communications|April 14, 2021
Identifying therapeutic drug targets using bidirectional effect genesKarol Estrada, Steven Froelich, Arthur Wuster, et al.
Journal of the National Cancer Institute|April 5, 2014
Role in tumor growth of a glycogen debranching enzyme lost in glycogen storage diseaseSunny Guin, Courtney Pollard, Yuanbin Ru, et al.
Molecular Therapy. Methods & Clinical Development|August 11, 2020
Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific PromoterSylvia Fong, Britta Handyside, Choong-Ryoul Sihn, et al.
JAMA Oncology|May 5, 2017
Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome AtlasDezheng Huo, Hai Hu, Suhn K Rhie, et al.
Oncotarget|February 18, 2017
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancerC Allison Stewart, Pan Tong, Robert J Cardnell, et al.
Plos One|January 3, 2025
Intracerebroventricular administration of a modified hexosaminidase ameliorates late-stage neurodegeneration in a GM2 mouse modelManuel E Lopez, Daniel Wendt, Roger Lawrence, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The Lancet. Oncology|January 25, 2011
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessmentSteven Christopher Smith, Alexander Spyridon Baras, Garrett Dancik, et al.
Annals of Clinical and Translational Neurology|December 10, 2019
Neurofilament light is a treatment-responsive biomarker in CLN2 diseaseYuanbin Ru, Carley Corado, Russell K Soon, et al.
Military Medicine|November 1, 2017
Comparative Survival Analysis of Invasive Breast Cancer Patients Treated by a U.S. Military Medical Center and Matched Patients From the U.S. General PopulationYuanbin Ru, Jianfang Liu, J Leigh Fantacone-Campbell, et al.
Nature Communications|April 14, 2021
Identifying therapeutic drug targets using bidirectional effect genesKarol Estrada, Steven Froelich, Arthur Wuster, et al.
Journal of the National Cancer Institute|April 5, 2014
Role in tumor growth of a glycogen debranching enzyme lost in glycogen storage diseaseSunny Guin, Courtney Pollard, Yuanbin Ru, et al.
Molecular Therapy. Methods & Clinical Development|August 11, 2020
Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific PromoterSylvia Fong, Britta Handyside, Choong-Ryoul Sihn, et al.
JAMA Oncology|May 5, 2017
Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome AtlasDezheng Huo, Hai Hu, Suhn K Rhie, et al.
Oncotarget|February 18, 2017
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancerC Allison Stewart, Pan Tong, Robert J Cardnell, et al.
Plos One|January 3, 2025
Intracerebroventricular administration of a modified hexosaminidase ameliorates late-stage neurodegeneration in a GM2 mouse modelManuel E Lopez, Daniel Wendt, Roger Lawrence, et al.
Pageof 2